Personalized heparin calculator aims to speed up clot treatment

NCT ID NCT07250763

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether using a patient's gender, weight, and kidney function to calculate the starting dose of the blood thinner heparin gets patients to the right level faster than the standard flat rate. About 145 adults with blood clots, atrial fibrillation, or mechanical heart valves will receive a personalized starting dose. The goal is to see if this approach reduces time to effective treatment and lowers the risk of over- or under-dosing.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
unfractionated heparin (blood thinner)
What this could lead to
If successful, this could make heparin treatment safer and more effective by reaching the right dose faster, reducing complications from clots or bleeding.
What could go wrong
This is a small, single-center study comparing against historical data, not a randomized trial. The personalized calculator may not work better in all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CARDIAC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Inova Alexandria Hospital

    Alexandria, Virginia, 22304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.